Cosmo Pharmaceuticals on Friday reported the renewal of its multi-year manufacturing and supply agreement with Takeda ...

Cosmo Pharma & Takeda renew strategic manufacturing pact for global supply of oral treatment for ulcerative colitis: Dublin, Ireland Saturday, August 9, 2025, 15:00 Hrs [IST] Cosm ...

Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines.

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net ...

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub TM and HyHub TM Duo, devices for patients 17 years of age and older ...

Rio Takeda and Eri Okayama are leading a strong Japanese showing in the Women's British Open. Takeda and Okayama share the ...

Leo Barella, a former executive at Takeda, has joined Booz Allen Hamilton as senior vice president and chief information ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse generics. Learn why TAK stock is a buy.

Takeda Pharmaceutical Co.’s 2019 acquisition of its larger European rival Shire PLC made it one of the most indebted drugmakers in the world. Four years later, Takeda has not only brought its ...

August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply ...